Focus: Moderna is a Cambridge-based mRNA therapeutics company with 5,900 employees and a $6.8B revenue run rate (FY2025), focused on vaccines and oncology across infectious disease and rare disease indications. The company is a public, large-cap biotech leader in the mRNA space with proven commercial execution via Spikevax.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Hot — 64 jobs added in 30d
Net +26 (64 new, 38 removed). Aggressive expansion phase.
Moderna is a high-growth mRNA platform play with significant near-term pipeline catalysts and hiring momentum, but faces revenue volatility and burn-rate risk that demands strong pipeline execution.
Flagship product with global adoption but facing endemic demand normalization post-pandemic; multiple variant formulations in development (mRNA-1273.214, mRNA-1283, mRNA-1273.211).
Help build intelligence for Moderna
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Moderna's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
BLA-approved vaccine in growth phase with Phase 3 data supporting label expansion; represents key non-COVID revenue diversification.
Specialized COVID formulation targeting high-risk populations; emerging niche market with limited upside.
8-K Filing: Invivyd, Inc. (IVVD) (CIK 0001832038) — EX-99.2
EX-99.2
8-K Filing: Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) — CORPORATE PRESENTATION, MARCH 31, 2026
CORPORATE PRESENTATION, MARCH 31, 2026
8-K Filing: Eikon Therapeutics, Inc. (EIKN) (CIK 0001861123) — EX-99.1
EX-99.1
8-K Filing: Roivant Sciences Ltd. (ROIV) (CIK 0001635088) — EXHIBIT 10.1
EXHIBIT 10.1
8-K Filing: Pyxis Oncology, Inc. (PYXS) (CIK 0001782223) — EX-99.1
EX-99.1
8-K Filing: CytomX Therapeutics, Inc. (CTMX) (CIK 0001501989) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults.
Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo